Table 3 Baseline characteristics studies
From: Melatonin as a treatment for migraine sufferers: a systematic review
Authors | Country | Study design | Periods | Mean age (years) | Total participants |
|---|---|---|---|---|---|
Gelfand et al. (2020) | USA | Randomized 1:1 Not blinded Home-based trial | 4 months | 11.8 | 84 |
Gelfand et al. (2017) | USA | Randomized, double-blind, placebo-controlled pilot | 3 months | 12–17 | 26 |
Alstadhaug et al. (2010) | Norway | Randomized, double-blind, placebo-controlled, crossover | 2 months | 41.9 ± 9.2 | 48 |
Ebrahimi-Monfared et al. (2017) | Iran | Randomized, double-blind, placebo-controlled clinical trial | 2 months | 38.9 ± 9.2 | 105 |
Gonçalves et al. (2016) | Brazil | Randomized, double-blind, placebo controlled | 3 months | 36.9 ± 10.1 | 178 |